Thelansis

Atrophic Vaginitis (Vaginal Atrophy) Market Outlook Thelansis’s “Atrophic Vaginitis (Vaginal Atrophy) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrophic Vaginitis (Vaginal Atrophy) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

  Atrophic Vaginitis (Vaginal Atrophy) Market Outlook Thelansis’s “Atrophic Vaginitis (Vaginal Atrophy) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrophic Vaginitis (Vaginal Atrophy) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Atrophic Vaginitis (Vaginal Atrophy) Overview Atrophic vaginitis is an inflammatory condition associated with vaginal atrophy caused by reduced estrogen levels, mainly occurring during menopause. Vaginal atrophy leads to thinning of the vaginal epithelium, decreased vaginal rugae and elasticity, and reduced vaginal secretions. It affects pre-menopausal women and up to 50% of post-menopausal wome...

  Atrophic vaginitis is an inflammatory condition associated with vaginal atrophy caused by reduced estrogen levels, mainly occurring during menopause. Vaginal atrophy leads to thinning of the vaginal epithelium, decreased vaginal rugae and elasticity, and reduced vaginal secretions. It affects premenopausal women and up to 50% of postmenopausal women. The hypoestrogenic state responsible for atrophic vaginitis can result from natural menopause or be induced by medical interventions like surgery, radiation, chemotherapy, or certain medications such as Selective estrogen receptor modulators, Selective estrogen receptor degraders, and antigonadotropins. Lower estrogen levels cause alterations in the vaginal environment, disrupting the normal flora, leading to an overgrowth of skin and rectal pathogens due to decreased Lactobacillus spp. The diagnosis of atrophic vaginitis is typically based on the patient's history and specific physical examination findings. Symptoms include vagina...